AAV-CNGA3 / J&J, MeiraGTx 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  AAV-CNGA3 / J&J, MeiraGTx, entacingene turiparvovec (AAV-CNGB3) / J&J
    Trial completion, Trial completion date, Trial primary completion date, Gene therapy:  Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3 (clinicaltrials.gov) -  May 3, 2024   
    P1/2,  N=34, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Apr 2024 | Trial primary completion date: Jan 2026 --> Apr 2024
  • ||||||||||  AAV-CNGA3 / J&J, MeiraGTx
    Preclinical, Journal:  A Bioengineered In Vitro Model to Assess AAV-Based Gene Therapies for Cyclic GMP-Related Disorders. (Pubmed Central) -  May 21, 2022   
    Using this system, we were able to confirm and quantify the function of the ion channel encoded by AAV/CNGA3 and differentiate between AAV vector potencies with a simple fluorometric assay. Finally, we show that this approach can be readily adapted for the assessment of phosphodiesterase function.
  • ||||||||||  AAV-CNGA3 / J&J, MeiraGTx, entacingene turiparvovec (AAV-CNGB3) / J&J
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Gene therapy:  Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3 (clinicaltrials.gov) -  Jan 14, 2022   
    P1/2,  N=34, Active, not recruiting, 
    Finally, we show that this approach can be readily adapted for the assessment of phosphodiesterase function. Recruiting --> Active, not recruiting | N=72 --> 34 | Trial completion date: Aug 2024 --> Jan 2026 | Trial primary completion date: Jul 2024 --> Jan 2026
  • ||||||||||  AAV-CNGA3 / J&J, MeiraGTx
    Trial completion, Enrollment change, Trial completion date, Gene therapy:  Gene Therapy for Achromatopsia (CNGA3) (clinicaltrials.gov) -  Jun 25, 2021   
    P1/2,  N=11, Completed, 
    Recruiting --> Active, not recruiting | N=72 --> 34 | Trial completion date: Aug 2024 --> Jan 2026 | Trial primary completion date: Jul 2024 --> Jan 2026 Recruiting --> Completed | N=18 --> 11 | Trial completion date: Jan 2022 --> Jun 2021
  • ||||||||||  AAV-CNGA3 / J&J, MeiraGTx, entacingene turiparvovec (AAV-CNGB3) / J&J
    Enrollment change, Trial completion date, Trial primary completion date, Gene therapy:  Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3 (clinicaltrials.gov) -  Sep 11, 2019   
    P1/2,  N=72, Recruiting, 
    Recruiting --> Completed | N=18 --> 11 | Trial completion date: Jan 2022 --> Jun 2021 N=18 --> 72 | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Jul 2023 --> Jul 2024
  • ||||||||||  AAV-CNGA3 / J&J, MeiraGTx
    Enrollment open, Trial initiation date, Gene therapy:  Gene Therapy for Achromatopsia (CNGA3) (clinicaltrials.gov) -  Jul 28, 2019   
    P1/2,  N=18, Recruiting, 
    N=18 --> 72 | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Jul 2023 --> Jul 2024 Not yet recruiting --> Recruiting | Initiation date: Mar 2019 --> Jul 2019
  • ||||||||||  AAV-CNGA3 / J&J, MeiraGTx
    New P1/2 trial, Gene therapy:  Gene Therapy for Achromatopsia (CNGA3) (clinicaltrials.gov) -  Nov 29, 2018   
    P1/2,  N=18, Not yet recruiting,